biospecimen banks

CPDR Patient Education Program

Helpful Resources

 

Agent Orange and Prostate Cancer

Veterans diagnosed with prostate cancer may qualify for service-connected disability compensation.
Information Sheet

 

Special Clinic at WRNMMC for Men with Prostate Cancer

The Center for Prostate Disease Research (CPDR) at Walter Reed National Military Medical Center (WRNMMC) has a special clinic for men diagnosed with prostate cancer called the "Multi-Disciplinary Prostate Cancer Clinic".
More Information

 

Patient Education Links

American Cancer Society
Website: Cancer.Org
Phone: 800-ACS-2345

National Cancer Institute
Website: Cancer.Gov
Phone: 800-4-CANCER

National Comprehensive Cancer Network
Website: www.nccn.com

Us TOO International Prostate Cancer Education and Support Network
Website: www.ustoo.org
Phone: 800-808-7866

American Urological Association
Website: www.urologyhealth.org
Phone: 800-828-7866

Prostate Cancer Research Institute
Website: www.prostate-cancer.org
Phne: 800-641-7274

 

Newsletters

Choices
Website: www.paactusa.org
Phone: 616-453-1477

PCRI Insights
Website: www.pcri.org
Phone: 310-743-2117

The John Hopkins Prostate Bulletin
Phone: 800-829-0422

Us TOO Hotsheets
Website: www.ustoo.org

WRNMMC Us TOO Newsletter
Website: cpdr.org
Phone: 301-319-2918

CURRENT EVENTS


August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

 

WRNMMC UsToo! Newsletter

Read the AUGUST 2014 Newsletter